Pharvaris股票由Wedbush升级，目标价为42美元，表现优于股价。 
Pharvaris stock upgraded by Wedbush to outperform with $42 target.
韦德布什将法华瑞升级为"超越",目标价42美元,理由是对其治疗遗传性血管的口服药物的信心. Wedbush upgraded Pharvaris to "outperform" with a $42 price target, citing confidence in its oral treatment for hereditary angioedema. 尽管大家一致认为该股票的评级为"适度买入", 但一些分析师却下调了它的评级. Despite a consensus "Moderate Buy" rating, some analysts have downgraded the stock. 利公司开发PHA121, 市值为154亿美元,收益比负,股票表现波动. Pharvaris, developing PHA121, has a market cap of $1.54 billion, a negative P/E ratio, and volatile stock performance.
